Clinical trials: Glucagon
Hyperglycemia
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans
The purpose of this study is to determine the dose of the GLP-1 receptor antagonist exendin(9-39) which blocks the insulinotropic action of synthetic GLP-1 by at least 95%.
- Trial name
- NCT00393445
- Testing
- GLP-1 control, GLP-1 and Exendin(9-39) 300, saline control
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Hypoglycemia, Diabetes Mellitus, Type 1
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus…
- Trial name
- NCT03339453
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 2 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Endocrine System Diseases
Oral Glucose Stimulation in Normal-weight and Obese Volunteers
The objective of this study is to examine gastric emptying and satiety hormones after oral glucose stimulation in 2 different concentrations in normal-weight and obese patients.
- Trial name
- NCT01875575
- Testing
- Glucose 25g, Glucose 10g
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Obesity
Comparison of Body Composition Changes With Weight Loss Interventions
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time.
- Trial name
- REFORM (NCT07115069)
- Testing
- GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01744236
- Testing
- Liraglutide, Sitagliptin, Exenatide
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Hypoglycemia, Hypoglycemia, Reactive
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia
The purpose of the study is to determine how blood sugar levels in individuals with and without hypoglycemia after bariatric surgery respond to different doses of glucagon, a hormone that is usually present in your body that…
- Conditions
- Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
- Trial name
- NCT06986603
- Testing
- Glucagon for Injection (Fresenius Kabi USA)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Joslin Diabetes Center
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03439072
- Testing
- G-Pen, Lilly Glucagon
- Where
- 6 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Xeris Pharmaceuticals
Hypoglycemia
Post Bariatric Closed Loop Glucagon Trial
This study is to test our automated hypoglycemia prevention and treatment device (glucagon-only bionic pancreas) in subjects that have undergone post-bariatric surgery that are experiencing symptoms of hypoglycemia.
- Trial name
- NCT02966275
- Testing
- Glucagon-only bionic pancreas - glucagon
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes Mellitus
The Postprandial Hypo-Avoid Study
The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity…
- Trial name
- NCT07427251
- Testing
- Low-Dose Glucagon, Glucose Arm
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Steno Diabetes Center Copenhagen
Residual Gastric Contents, Delayed Gastric Emptying
GLP-1 RA Cessation and Gastric Ultrasound Findings
This prospective observational study will evaluate the association between the time interval since the last dose of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and residual gastric contents before elective surgery.
- Trial name
- NCT07623148
- Testing
- GLP-1 RA Cessation Interval
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Wonkwang University Hospital
Coronary Artery Disease
Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?
In this study, the investigators hypothesized that significant proportion of patients with coronary artery disease (CAD) has reduced capacity of glucagon-like peptide-1 (GLP-1) secretion, which is detectable as blunted response…
- Trial name
- NCT02280837
- Testing
- Determination of plasma GLP-1 level
- Where
- Japan
- Volunteers
- 190 people
- Sponsor
- Sapporo Medical University
Diabetes Mellitus Type 1
The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas
This study will compare two different models of a wearable bionic pancreas device (the iPhone-based bionic pancreas vs. the iLet bionic pancreas) in adult participant with type 1 diabetes.
- Trial name
- NCT02701257
- Testing
- iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Hyperinsulinemic Hypoglycemia
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial…
- Trial name
- NCT03770637
- Testing
- Glucagon RTU
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Xeris Pharmaceuticals
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Hyperglucagonemia, Hyperglycemia
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
In order to evaluate the potential role of the gastrointestinal (GI) tract in the postprandial hyperglucagonemia, which characterizes type 1 diabetes mellitus (T1DM) (as well as type 2 diabetes mellitus (T2DM)), we wish to…
- Conditions
- Hyperglucagonemia, Hyperglycemia, Diabetes Mellitus
- Trial name
- NCT00704795
- Testing
- Oral glucose tolerance test, Isoglycemic iv glucose infusion
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Healthy
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal.
- Trial name
- NCT04459338
- Testing
- Exendin-9,39, Saline
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Healthy Volunteers
The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants
This is a study to measure the effect that various doses of LY2409021 have on blood sugar levels and on the amount of glucose released by the liver, when glucagon is given to increase these.
- Trial name
- NCT01606423
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
- Trial name
- NCT02887625
- Testing
- Pioglitazone plus exenatide, insulin glargine and insulin aspart
- Where
- Qatar
- Volunteers
- 410 people
- Sponsor
- Dr. Muhammad Abdulghani
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes
This mechanistic study is designed to investigate the effect of vildagliptin on the sensitivity of the a-cell to glucose under hypoglycemic conditions in patients with type 2 diabetes (T2DM).
- Trial name
- NCT00390520
- Testing
- Vildagliptin
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Novartis
Obesity
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
- Trial name
- NCT04186026
- Testing
- Saline + saline, Neurotensin + saline, GLP-1 + saline
- Where
- 2 sites in Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen